Global MicroRNA Market - 2022-2029

Global MicroRNA Market - 2022-2029
Market Overview

MicroRNA Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 19.3 % during the forecast period (2022-2029).

MicroRNAs (or miRNAs) are a new class of tiny, non-coding endogenous RNAs that control gene expression by targeting mRNAs for destruction or translational suppression. Their discovery expanded the understanding of complicated gene regulation networks in humans and animals. miRNAs influence many areas of development and physiology. Understanding its biological role is thus becoming increasingly crucial. miRNA expression analysis may provide useful information because deregulation of its function can lead to human disorders such as cancer, cardiovascular and metabolic diseases, liver problems, and immunological dysfunction.

Market Dynamics

Advances in the COVID-19 mRNA vaccine development are expected to drive market growth.

The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has resulted in 399,600,607 cases and 5,757,562 deaths globally. COVID-19 is a severe hazard to human health around the world. The COVID-19 pandemic has been labeled a global public health emergency by the World Health Organization (WHO). Vaccination is the most successful and cost-efficient method for preventing the spread of the epidemic, saving lives and protecting population health. COVID-19 vaccines have been developed using a variety of ways. Among these, the COVID-19 messenger RNA (mRNA) vaccine has received increased attention due to its broad application potential and benefits, which include a short development cycle, ease of industrialization, a simple manufacturing process, the ability to respond to new variants, and the ability to induce a stronger immune response.

Moreover, researchers have long sought to use mRNA vaccines for cancer treatment. For nearly a decade, mRNA-based cancer therapy vaccines have been studied in modest studies, with some encouraging early findings. For instance, Pfizer-BioNTech and Moderna used their experience generating mRNA cancer vaccines to build coronavirus vaccines. Some researchers anticipate that the effectiveness of the mRNA COVID-19 vaccines may help advance clinical research on mRNA vaccines for cancer treatment. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs associated with the miRNA kits are time-consuming, making the accurate computational prediction of miRNA targets a high priority; safety and toxicity issues of miRNA are some of the factors the market is expected to get hampered in the forecast period.

Industry Analysis

The microRNA market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. miRNAs can inhibit the viral translation after the attachment of miRNAs to 3′-UTR of the viral genome or target the receptors, structural or nonstructural proteins of SARS-CoV-2 without affecting the expression of human genes. For instance, ID02510.3p-miRNA, ID00448.3pmiRNA, miRNA 3154, miRNA 7114-5p, miRNA 5197-3p, ID02750.3p-miRNA, and ID01851.5p-miRNA attenuate COVID-19 disease development by binding to the SARS-CoV-2 genome and inhibiting its post-transcriptional expression. Nersisyan et al. identified six miRNAs, including miR-21-3p, miR-195-5p, miR-16-5p, miR-3065-5p, miR-424-5p, and miR-421, that could regulate all human coronaviruses by binding directly to the viral genome. The best binding to the human coronavirus genome was found at miR-21-3p. Therefore, because of the increased COVID-19 infection, there is a greater need for effective therapy, which raises the demand for next-generation sequencing technologies and miRNA sequencing.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Real Time Polymerase Chain Reaction segment is expected to hold the largest market share in microRNA market

The real-time polymerase chain reaction segment is expected to dominate in 2021. The segment benefits because it has a wide dynamic range, excellent sensitivity, can be very sequence-specific, requires little to no post-amplification processing, and can be scaled up to increase sample throughput. Moreover, the research of gene expression has been transformed by RT-PCR. The RNA transcript of any gene can now theoretically be detected, regardless of the scarcity of the starting material or the relative abundance of the specific mRNA. RT-PCR involves using a retroviral reverse transcriptase to copy an RNA template into complementary DNA (cDNA). PCR is then used to amplify the cDNA exponentially. RT-PCR, like NPAs, is fairly tolerant of degraded RNA. The target will be amplified if the RNA is intact inside the region spanned by the primers.

Moreover, Tata MD launched COVID express RT-PCR testing solutions in December 2021. Tata MD CHECK XF, a 3-Gene RT-PCR kit that does not require RNA extraction and uses a fast amplification procedure, is combined with a portable and quick qPCR analyzer and Tata MD CHECK RT-PCR Fast 3 Gene. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global microRNA market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer and infectious diseases, rising demand for next-generation and microRNA services and applications in drug development, adoption of the latest technology, and established research infrastructure for proteomics, genomics, and oncology, rising patent approvals for their miRNA biomarkers and product launches by the key market players are some of the factors the market is expected to boost in the forecast period. For instance, in the United States, in 2019, 1,752,735 new cancer cases were reported, and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported, and 146 people died of cancer. In contrast, In the United States, however, 2 million new cancer cases were identified in 2020, with 612,390 deaths. This shows that the cancer incidence and mortality rate are very high, increasing the demand for precision medications and therapies for patients and raising the demand for microRNA approaches in the region.

Moreover, On Oct. 21, 2021, Interpace Biosciences, Inc. announced that the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for the use of microRNAs in the differentiation of benign from malignant thyroid neoplasms. This patent covers the technology that underpins its ThyraMIR microRNA Classifier. MicroRNAs are short non-coding RNAs that bind to messenger RNA and influence protein expression in human malignancies, including thyroid cancer. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the microRNA market are Qiagen N.V., Illumina, Inc., Takara Bio, Inc, PerkinElmer, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Abcam Plc, GeneCopoeia, Inc., System Biosciences LLC, Miltenyi Biotec.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

TaqMan miRNA Assays: TaqMan MicroRNA Assays from Applied Biosystems quantify miRNAs using the specificity and sensitivity of TaqMan Assay chemistry. A straightforward two-step approach consists of reverse transcription using a miRNA-specific primer, followed by real-time PCR using TaqMan probes. TaqMan MicroRNA Assays are highly specific, sensitive, quick, easy to use, and scalable.

The global microRNA market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.